Ajay Sawhney 
Corporate & In-House News

Exclusive: Cyril Amarchand Mangaldas Partner and Northern Region Head Ajay Sawhney leaves to join AZB & Partners

Sawhney has been associated with CAM for the past decade.

Bar & Bench

Cyril Amarchand Mangaldas Partner and Northern Region Head Ajay Sawhney has resigned from the firm and is moving to AZB & Partners as an Equity Partner, according to reliable sources.

Confirming his exit, Cyril Amarchand Mangaldas Managing Partner, Cyril Shroff said,

“Ajay has been a valuable member of the firm. He has served CAM well. We wish him all the best in life and all success in his future endeavours."

We have reached out to AZB & Partners for comment.

Sawhney is a 2003 graduate of Symbiosis Law School, Pune. He earned his LLM from the University of Liverpool in 2004.

With over two decades of experience, Sawhney specialises in projects and construction law. He advises various business groups on acquisitions, project financing, and construction and development, with a focus on both domestic and international projects. He has provided advisory services to banks and financial institutions on prominent lending transactions within the infrastructure sector across the Asia Pacific region.

As the Head of the Northern Region, Sawhney led CAM's Noida office. His previous engagements include a short 1-year stint at K Law and a decade at Link Legal.

It is understood that few more team members may be leaving with Sawhney to join AZB.

This is a developing story.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Supreme Court asks Centre to consider framing rules to regulate social media accounts of minors

Karnataka HC quashes FIR against BJP's Chalavadi Narayanaswamy, TS Srivatsa over remarks about ST status to Kurubas

Collegium recommends 3 new judges for Supreme Court

Delhi High Court to decide personality rights cases of 3 celebrities together

Kerala High Court invokes Mammooty's 1994 movie, says plight of cancer patients remains unchanged

SCROLL FOR NEXT